Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

Aletaha D(2008)The importance of reporting disease activity states in rheumatoid arthritis clinical trials Arthritis Rheum 58 2622-2631

Funovits J(2016)Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 75 3-15

Smolen JS(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

Smolen JS(2010)Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 22-54

Breedveld FC(2012)A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry Ann Rheum Dis 71 1134-1142

Burmester GR(2014)Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival Semin Arthritis Rheum 43 447-457

Bykerk V(2015)Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry Rheumatology (Oxford) 54 1664-1672

Dougados M(2015)Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register Rheumatology (Oxford) 54 1186-1193

Emery P(2015)Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort Ann Rheum Dis 74 724-729

Smolen JS(2016)Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds Ann Rheum Dis 75 2080-2086

Aletaha D(2008)The importance of reporting disease activity states in rheumatoid arthritis clinical trials Arthritis Rheum 58 2622-2631

Funovits J(2016)Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 75 3-15

Smolen JS(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

Smolen JS(2010)Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 22-54

Breedveld FC(2012)A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry Ann Rheum Dis 71 1134-1142

Burmester GR(2014)Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival Semin Arthritis Rheum 43 447-457

Bykerk V(2015)Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry Rheumatology (Oxford) 54 1664-1672

Dougados M(2015)Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register Rheumatology (Oxford) 54 1186-1193

Emery P(2015)Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort Ann Rheum Dis 74 724-729

Smolen JS(2016)Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds Ann Rheum Dis 75 2080-2086